SCHEDULE 13D/A: Activist Investor Opposes Aadi Bioscience's Strategic Shift, Citing Rejected Acquisition Offer and Shareholder Dilution

An activist investor group, BML Investment Partners, L.P. and Braden M. Leonard, has filed an amended Schedule 13D, publicly opposing Aadi Bioscience, Inc.'s proposed strategic transactions, including an asset sale and significant share dilution, in favor of a previously rejected acquisition offer.

Summary

• BML Investment Partners, L.P. and Braden M. Leonard collectively beneficially own 2,435,000 shares of Aadi Bioscience, Inc. common stock, representing 9.9% of the class.
• The reporting persons are voting against all proposals at Aadi Bioscience's upcoming Special Meeting of Stockholders on February 28th.
• They allege that Aadi Bioscience's Board of Directors turned down a superior offer from "Kraken" on October 17, 2024, to acquire the entire company.
• The initial Kraken bid valued Aadi's FYARRO business at $80 million on a cash-free, debt-free basis, which, combined with $40 million to $50 million in estimated excess cash, amounted to $4.38 to $4.74 per share.
• The Kraken bid was reportedly raised by $20 million in December, increasing the potential per-share value to $5.12 to $5.48 in cash.
• Instead, the Board is proposing a $100 million asset sale of FYARRO, retaining 100% of the proceeds to fund the in-licensing of three pre-clinical molecules from China.
• The company plans to issue 41.66 million shares and pre-funded warrants at $2.40 per share, which would dilute current shareholders by over 60%.
• The in-licensed drugs are not expected to be ready for clinical trials for another 12 to 24 months and would require several years of late-stage trials and potentially hundreds of millions in cash burn before generating revenue.

Sentiment

Score: 2

Explanation: The document, specifically the attached letter from the reporting person, conveys a strongly negative sentiment regarding Aadi Bioscience's Board decisions. It highlights a rejected superior offer, significant shareholder dilution, and a high-risk strategic pivot, all framed as detrimental to shareholder value.

Positives

• The reporting persons are actively advocating for what they believe is maximizing shareholder value by highlighting a previously rejected acquisition offer.
• The disclosure provides transparency regarding a significant alternative transaction that was considered by the Board.

Negatives

• Aadi Bioscience's Board allegedly rejected an offer to buy the entire company for $5.12 to $5.48 per share in cash.
• The Board is instead pursuing an asset sale of FYARRO for $100 million, with proceeds not directly distributed to shareholders.
• The company plans a significant dilutive capital raise, issuing 41.66 million shares and pre-funded warrants at $2.40 per share, less than half the rejected acquisition price.
• This proposed transaction would dilute current shareholders' ownership by over 60%.
• The proceeds from the FYARRO sale and the capital raise are intended to fund the in-licensing and development of three pre-clinical molecules, which are high-risk, long-term assets.
• These new drugs are not expected to enter clinical trials for 12 to 24 months and will require substantial future cash burn.

Risks

• Significant shareholder dilution from the proposed issuance of 41.66 million shares and pre-funded warrants.
• High risk associated with developing pre-clinical assets, as they require extensive and costly clinical trials with uncertain outcomes.
• Substantial future cash burn, potentially in the hundreds of millions of dollars, required to advance the in-licensed molecules through development.
• Long development timelines (12-24 months to clinic, several years for late-stage trials) for the new drug candidates, delaying potential revenue generation.
• Potential for continued shareholder dissatisfaction and corporate governance challenges due to the Board's strategic decisions.

Future Outlook

Aadi Bioscience plans to use the proceeds from the FYARRO asset sale and a significant capital raise to fund the in-licensing and development of three pre-clinical molecules from China. These drugs are projected to enter clinical trials in 12 to 24 months, followed by several years of late-stage trials, requiring substantial future cash burn before any potential revenue generation.

Management Comments

• "The Board of Directors has recently issued two letters extolling the virtues of the proposals they're asking shareholders to approve on February 28th."
• "What the Board doesn't mention in either letter is that it turned down an offer that was far superior to what it's asking us to vote in favor of one that would have instantly doubled the stock price instead of diluting us all by over 60% at a terrible price."
• "BML is emphatically voting NO to all proposals and believes other self-interested shareholders should do the same."

Industry Context

This filing highlights a common challenge in the biotech and pharmaceutical industry: balancing immediate shareholder value with long-term strategic investments in drug development. The decision to pursue high-risk, pre-clinical assets over a definitive acquisition offer reflects a strategic pivot towards pipeline expansion, a common strategy for growth-oriented biotechs, but one that carries significant financial and clinical risks. The activist investor's stance underscores the tension between short-term shareholder returns and long-term R&D investments, particularly when a clear exit opportunity is presented.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results.
• However, the activist investor's argument implies that rejecting a cash offer of over $5 per share in favor of a dilutive capital raise at $2.40 per share and investment in early-stage assets is not in line with best practices for maximizing immediate shareholder value.
• In the biotech sector, M&A offers often represent a significant premium, and rejecting such offers for unproven, long-term assets can be viewed critically by investors seeking near-term returns or risk mitigation.

Corporate Governance

Stakeholder Impact

• Shareholders: Face significant dilution (over 60%) and a potential loss of value compared to a rejected acquisition offer. Their investment is being redirected towards high-risk, long-term pre-clinical drug development.
• Management/Board: Under scrutiny from activist investors for their strategic decisions and perceived failure to maximize shareholder value. Their proposals are being directly challenged.
• Employees: Potential long-term impact depending on the success or failure of the new drug development pipeline.

Next Steps

• Aadi Bioscience's Special Meeting of Stockholders is scheduled for February 28th, where shareholders will vote on the proposed transactions.
• BML Investment Partners, L.P. and Braden M. Leonard intend to vote "NO" to all proposals.
• The company will proceed with the in-licensing and development of three pre-clinical molecules if the proposals are approved, with clinical trials expected to begin in 12 to 24 months.

Key Dates

Recommendation

Keywords

Aadi Bioscience, Schedule 13D, shareholder activism, corporate governance, stock dilution, asset sale, biotech, pharmaceutical, FYARRO, Kraken, investment, proxy vote, special meeting, pre-clinical assets, capital raise